Navigation Links
Generex Biotechnology Vaccine Strategy Presented at International,Conference in London

latform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.


Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be reg
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
11. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
Post Your Comments:
(Date:7/28/2015)... , July 28, 2015  Insulet Corporation (NASDAQ: ... with its OmniPod ® Insulin Management System, today ... appointed to Insulet,s Board of Directors. Dr. ... experience to the Insulet Board. She currently serves as ... Diabetes Center, the world,s largest diabetes research center, diabetes ...
(Date:7/28/2015)... July 28, 2015  Express Scripts Holding Company (Nasdaq: ... attributable to Express Scripts stockholders of $600.1 million, or ... as detailed in Table 4, were $1.44 for the ... clear many companies across healthcare are validating the need ... Chief Executive Officer. "But, what matters most is how ...
(Date:7/28/2015)... PARK, Calif. , July 28, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based ... announced the publication of the SENZA-RCT results in ... official Journal of the American Society of Anesthesiologists. ... a ground-breaking study that was the first to ...
Breaking Medicine Technology:Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 2Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 13Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 14Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 15Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 16Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 17Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 18Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 19Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 20Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 21Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 22Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 24Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 25Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2
... WMT ) announced today the availability of atorvastatin ... immediately for patients with valid prescriptions. The all-new generic ... Lipitor® provides a more affordable medication option for the millions ... to heart disease or are at risk for developing ...
...  Clinical Investigators for Arstasis, Inc., reported the results ... Meeting in San Francisco, demonstrating the Arstasis access ... arteries after cardiac catheterization procedures. The device creates ... the femoral artery through which catheterization procedures are ...
Cached Medicine Technology:Walmart Announces Generic Lipitor® (Atorvastatin Calcium Tablets) Available in Stores Today 2RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure 2
(Date:7/29/2015)... ... 2015 , ... TransFlip is an all new dynamic transition pack for FCPX, ... these transitions are easy to apply and modify for any skill-level user. TransFlip includes ... preset styles, kinetic flipping panel animations are just a few clicks away. , TransFlip ...
(Date:7/29/2015)... ... 2015 , ... The New Foundation AZ recently started a massive ... cost the 501(c) organization nearly $1 million, will both update the facilities’ design and ... it down to the studs,” said Geraldine Leary, the New Foundation AZ chief executive ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... entered into a partnership with 247Ergo, an ergonomics specialty firm. Purpose of the ... projects that the companies undertake could improve worker mobility, functionality and fitness levels. ...
(Date:7/29/2015)... ... 29, 2015 , ... Elizabeth Callahan, M.D., founder and medical ... by the manufacturer to offer and perform Kybella™ under-chin fat ... and eliminate double chin fat,” Dr. Callahan explained. “Previously this area could only ...
(Date:7/29/2015)... TN (PRWEB) , ... July 29, 2015 , ... ... Value-Added Solutions Group, which Breckheimer oversees. In her role, Powers is responsible for ... Upon making the announcement, Breckheimer commented, “Gina’s track record as an effective leader ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 2Health News:SkinSmart Dermatology is First in Sarasota to Offer Kybella Treatments to Reduce Double Chin Fat 3Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 2Health News:Gina Powers Named Vice President & General Manager of ITW Dynatec 3
... The following is being,issued by The 100 Black Men of Atlanta, Inc.:, WHO: ... Atlanta Falcons Youth Foundation ... Girls Clubs of Metro Atlanta Retired ... health screening and fair for school-aged ...
... first quarter increased 80.6% compared to the first ... quarter 2007 to $23.8 million, - Gross profit for the first quarter increased ... first quarter of 2007 to $6.2 million ... history, HATBORO, Pa., April 30 InfoLogix, Inc.,(Nasdaq: IFLG ), a leading ...
... C. diff-associated disease (CDAD), otherwise known as severe intestinal ... pathogen, has been the subject of heightened concern in ... month by the federal Agency for Healthcare Research and ... diarrheal infections in U.S. hospitals between 2000 and 2005. ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) reported today its financial results for ... December 31, 2007 include:, Development:, -- Notified sites participating ... in stem cell transplant patients that enrollment will be complete by ... Patient enrollment continued in Phase 3 study of maribavir in solid ...
... GXDX ), a specialized laboratory services provider, today announced,the ... scheduled to take place at the Four Seasons Hotel ... Dr. Tina Nova Bennett, President and CEO of Genoptix, ... Tuesday, May 13, 2008,beginning at approximately 9:20am PDT. They ...
... muscles may provide an ... for frown lines, SAN MATEO, Calif., April 30 ... it has acquired substantially all of the,assets of privately-held, ... technology rights for $12 million cash, plus,future royalties and ...
Cached Medicine News:Health News:Media Alert: 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 2Health News:InfoLogix Announces First Quarter 2008 Financial Results 2Health News:InfoLogix Announces First Quarter 2008 Financial Results 3Health News:InfoLogix Announces First Quarter 2008 Financial Results 4Health News:InfoLogix Announces First Quarter 2008 Financial Results 5Health News:InfoLogix Announces First Quarter 2008 Financial Results 6Health News:InfoLogix Announces First Quarter 2008 Financial Results 7Health News:InfoLogix Announces First Quarter 2008 Financial Results 8Health News:InfoLogix Announces First Quarter 2008 Financial Results 9Health News:Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence 2Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 2Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 3Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 4Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 5Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 6Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 7Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 8Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 9Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 10Health News:Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference 2Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 2Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 3Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 4Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 5
... internal drainage from the ureteropelvic ... sterile in peel-open packages. Intended ... evaluation is advised; polyurethane, C-Flex, ... remain indwelling more than six ...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stenting the urethra during hypospadias or epispadias repair and to allow post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... for urethral stenting and ... following hypospadias repair. The ... be stabilized in the ... sutures at the meatus. ...
Medicine Products: